AURINIA PHARMACEUTICALS INC (AUPH) Stock Fundamental Analysis
USA - NASDAQ:AUPH - CA05156V1022 - Common Stock
11.75 USD
-0.09 (-0.76%)
AUPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While AUPH has a great health rating, its profitability is only average at the moment. AUPH is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, AUPH could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
In the past year AUPH was profitable.
AUPH had a positive operating cash flow in the past year.
In the past 5 years AUPH reported 4 times negative net income.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of AUPH (12.07%) is better than 94.76% of its industry peers.
The Return On Equity of AUPH (18.08%) is better than 95.32% of its industry peers.
AUPH has a Return On Invested Capital of 12.56%. This is amongst the best in the industry. AUPH outperforms 94.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.07% | ||
| ROE | 18.08% | ||
| ROIC | 12.56% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AUPH has a Profit Margin of 23.31%. This is amongst the best in the industry. AUPH outperforms 95.51% of its industry peers.
AUPH has a Operating Margin of 26.53%. This is amongst the best in the industry. AUPH outperforms 95.88% of its industry peers.
The Gross Margin of AUPH (89.51%) is better than 91.39% of its industry peers.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.53% | ||
| PM (TTM) | 23.31% | ||
| GM | 89.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AUPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AUPH has more shares outstanding
AUPH has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.87 indicates that AUPH is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.87, AUPH is doing good in the industry, outperforming 73.60% of the companies in the same industry.
AUPH has a debt to FCF ratio of 0.82. This is a very positive value and a sign of high solvency as it would only need 0.82 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.82, AUPH belongs to the top of the industry, outperforming 94.94% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that AUPH is not too dependend on debt financing.
AUPH's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. AUPH is outperformed by 67.23% of its industry peers.
Although AUPH does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.82 | ||
| Altman-Z | 4.87 |
ROIC/WACC1.47
WACC8.55%
2.3 Liquidity
A Current Ratio of 5.23 indicates that AUPH has no problem at all paying its short term obligations.
AUPH has a Current ratio (5.23) which is in line with its industry peers.
A Quick Ratio of 4.63 indicates that AUPH has no problem at all paying its short term obligations.
AUPH has a Quick ratio (4.63) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.23 | ||
| Quick Ratio | 4.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 243.33% over the past year.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 25.59%.
AUPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 279.17% yearly.
EPS 1Y (TTM)243.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1500%
Revenue 1Y (TTM)25.59%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%22.41%
3.2 Future
AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.12% yearly.
AUPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.58% yearly.
EPS Next Y634.77%
EPS Next 2Y193.81%
EPS Next 3Y118.33%
EPS Next 5Y68.12%
Revenue Next Year14.76%
Revenue Next 2Y14.54%
Revenue Next 3Y14.78%
Revenue Next 5Y12.58%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 27.33, which means the current valuation is very expensive for AUPH.
Based on the Price/Earnings ratio, AUPH is valued cheaper than 93.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of AUPH to the average of the S&P500 Index (27.77), we can say AUPH is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 15.12, the valuation of AUPH can be described as correct.
Based on the Price/Forward Earnings ratio, AUPH is valued cheaper than 94.94% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, AUPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.33 | ||
| Fwd PE | 15.12 |
4.2 Price Multiples
AUPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AUPH is cheaper than 95.51% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 96.07% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.74 | ||
| EV/EBITDA | 11.94 |
4.3 Compensation for Growth
AUPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 118.33% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y193.81%
EPS Next 3Y118.33%
5. Dividend
5.1 Amount
AUPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AUPH (10/22/2025, 10:35:18 AM)
11.75
-0.09 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.31%
Inst Owner Change0.09%
Ins Owners1.92%
Ins Owner Change-0.39%
Market Cap1.55B
Revenue(TTM)260.11M
Net Income(TTM)60.64M
Analysts81.54
Price Target11.95 (1.7%)
Short Float %7.37%
Short Ratio4.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.91%
Min EPS beat(2)6.95%
Max EPS beat(2)56.86%
EPS beat(4)4
Avg EPS beat(4)194.67%
Min EPS beat(4)6.95%
Max EPS beat(4)553.6%
EPS beat(8)7
Avg EPS beat(8)113.5%
EPS beat(12)11
Avg EPS beat(12)90.5%
EPS beat(16)13
Avg EPS beat(16)66.94%
Revenue beat(2)1
Avg Revenue beat(2)3.64%
Min Revenue beat(2)-0.48%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)15.16%
Revenue beat(8)5
Avg Revenue beat(8)8.08%
Revenue beat(12)9
Avg Revenue beat(12)11.98%
Revenue beat(16)13
Avg Revenue beat(16)10.05%
PT rev (1m)0%
PT rev (3m)15.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.29%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)0.92%
Revenue NQ rev (3m)4.65%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)4.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.33 | ||
| Fwd PE | 15.12 | ||
| P/S | 5.95 | ||
| P/FCF | 16.74 | ||
| P/OCF | 16.69 | ||
| P/B | 4.61 | ||
| P/tB | 4.67 | ||
| EV/EBITDA | 11.94 |
EPS(TTM)0.43
EY3.66%
EPS(NY)0.78
Fwd EY6.61%
FCF(TTM)0.7
FCFY5.97%
OCF(TTM)0.7
OCFY5.99%
SpS1.98
BVpS2.55
TBVpS2.52
PEG (NY)0.04
PEG (5Y)N/A
Graham Number4.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.07% | ||
| ROE | 18.08% | ||
| ROCE | 16.26% | ||
| ROIC | 12.56% | ||
| ROICexc | 48.78% | ||
| ROICexgc | 50.66% | ||
| OM | 26.53% | ||
| PM (TTM) | 23.31% | ||
| GM | 89.51% | ||
| FCFM | 35.52% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.82 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.54% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 104.75% | ||
| Profit Quality | 152.36% | ||
| Current Ratio | 5.23 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z | 4.87 |
F-Score8
WACC8.55%
ROIC/WACC1.47
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)243.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1500%
EPS Next Y634.77%
EPS Next 2Y193.81%
EPS Next 3Y118.33%
EPS Next 5Y68.12%
Revenue 1Y (TTM)25.59%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%22.41%
Revenue Next Year14.76%
Revenue Next 2Y14.54%
Revenue Next 3Y14.78%
Revenue Next 5Y12.58%
EBIT growth 1Y230.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7028.23%
EBIT Next 3Y378.96%
EBIT Next 5YN/A
FCF growth 1Y329.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y335.18%
OCF growth 3YN/A
OCF growth 5YN/A